Experimental and Clinical Transplantation最新文献

{"title":"A Rare Case of Plasmablastic Myeloma After Renal Transplant.","authors":"Sabir Sulejman, Ardian Memeti, Vlora Sadiku, Galina Severova, Gazmend Amzai, Nikola Gjorgjievski, Gordana Petrushevska, Goce Spasovski","doi":"10.6002/ect.2025.0148","DOIUrl":"https://doi.org/10.6002/ect.2025.0148","url":null,"abstract":"<p><p>Posttransplant lymphoproliferative disorders are a serious complication after solid-organ transplant, with a reported incidence from 2% to 20%. Plasma cell neoplasms in solid-organ transplants represent a rare but increasingly serious complication after solid-organ transplant. We report a case of plasmablastic myeloma, a very rare variant of multiple myeloma with aggressive course and poor prognosis. Few such cases have been reported in the literature in patients after solid-organ transplant. A 41-year-old male patient received a renal transplant from a living unrelated donor (wife) in 2019. After transplant, he was given triple immunosuppression therapy (mycophenolic acid, tacrolimus, prednisolone). In September 2024, 56 months after transplant, the patient presented to our nephrology department due to confusion, weight loss, loss of appetite, and gastric discomfort. Laboratory results showed hypercalcemia, elevated serum creatinine, and thrombocytopenia with anemia, without apparent blood loss. As a result of persistent hypercalcemia and elevated serum creatinine levels, treatment with hemodialysis was initiated. Polymerase chain reaction results were negative for Epstein-Barr virus. After preliminary preparation, bone marrow biopsy was performed, which revealed infiltration by cells with blastic morphology. Immunohistochemical analysis confirmed the finding with more than 80% of cells positive for CD138; the remaining marker tests were mostly negative. The day after the bone marrow biopsy, the patient had progressive deterioration in his health, with severe malaise and disorientation; he developed acute heart failure and pulmonary edema. An urgent hemodialysis was initiated, but it was unsuccessful. The patient died on day 10 of hospitalization. Posttransplant lymphoproliferative disorders and other malignant neoplasms pose a serious posttransplant complication in patients with challenging diagnoses due to overlapping features with other posttransplant complications; such patients most often experience a rapid and atypical course, due to high doses of immunosuppressants.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"23 8","pages":"555-559"},"PeriodicalIF":0.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence of Hepatocellular Carcinoma After Liver Transplant: A Single-Center Experience.","authors":"Aydan Farzaliyeva, Mehmet Nezir Ramazanoglu, Adem Safak, Arzu Oguz, Zafer Akcali, Ozden Altundag, Mehmet Haberal","doi":"10.6002/ect.2025.0041","DOIUrl":"https://doi.org/10.6002/ect.2025.0041","url":null,"abstract":"<p><strong>Objectives: </strong>Hepatocellular carcinoma is the fourth leading cause of cancer-related mortality worldwide, and almost all patients have simultaneous cirrhosis. For patients with hepatocellular carcinoma concurrent with cirrhosis, the best treatment option is liver transplant. With expansion of transplant criteria and increased use of liver transplant for treatment, median survival and recurrence rates in patients with hepatocellular carcinoma have also increased. Here, we evaluated tumor recurrence characteristics of hepatocellular carcinoma after liver transplant, treatments given, and survival periods.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed data of 512 patients who underwent transplant from January 2000 to December 2023 at Baskent University (Ankara, Turkey). We evaluated recurrence patterns, time to recurrence, and treatment survival outcomes among patients with or without recurrence.</p><p><strong>Results: </strong>Of 204 adult patients, 63 underwent transplant because of hepatocellular carcinoma. Of the 63 patients, 16 (25%) developed recurrence after liver transplant. Only 1 of the patients who developed recurrence was still alive at the time of this report. Of 16 patients, 50% had local and distant recurrence, 31% had distant metastasis, and 19% developed only local recurrence. Among patients, median overall survival was 65 months. Median survival was significantly lower in the recurrent group than in the nonrecurrent group (33 vs 49 mo; P = .001). Median time to recurrence was 11.6 months. Of the 63 patients, 32 patients (50.7%) underwent liver transplant by use of the expanded criteria developed in our center.</p><p><strong>Conclusions: </strong>Hepatocellular carcinoma requires a multidisciplinary approach. Although advances in interventional radiology, surgery, and medical oncologic treatment have prolonged survival in patients with hepatocellular carcinoma, hepatocellular carcinoma recurrence is still associated with poor prognosis. Management of recurrence remains an issue, with not enough data and single guidelines for management of hepatocellular carcinoma recurrence in immunosuppressed transplant recipients.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"23 8","pages":"542-545"},"PeriodicalIF":0.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late Effect of Early Phase COVID-19 on Outcomes of Kidney Transplant Recipients Who Survived the Acute Infection.","authors":"Arthur Gus Manfro, Eduarda Tais Schneider, Leonardo Luigi Adams Backes, Gabriel Petrolli, Rodrigo Fontanive Franco, Carla Elizabeth Oliveira Cezar, Andrea Carla Bauer, Roberto Ceratti Manfro","doi":"10.6002/ect.2025.0078","DOIUrl":"https://doi.org/10.6002/ect.2025.0078","url":null,"abstract":"<p><strong>Objectives: </strong>The COVID-19 pandemic has significantly affected global health, particularly among high-risk populations such as kidney transplant recipients, who have exhibited elevated morbidity and mortality rates. Long-term effects of COVID-19 in kidney transplant recipients who survived the infection are unknown. We evaluated the long-term effects of early phase COVID-19 on patient and graft survival, as well as graft function, in kidney transplant recipients who survived the acute phase of the COVID-19 infection.</p><p><strong>Materials and methods: </strong>We conducted a prospective, single-center cohort study involving kidney transplant recipients who survived COVID-19 from June 2020 to January 2022. Patients were stratified by disease severity and followed for 24 months. Data on renal function (estimated glomerular filtration rate and urinary protein-to-creatinine ratio) were collected at multiple time points. Statistical analyses were based on χ2 tests, analysis of variance, generalized additive mixed models, and Kaplan-Meier analyses.</p><p><strong>Results: </strong>Among 1477 kidney transplant recipients, 233 (15.8%) contracted COVID-19, with 60 (25.8%) fatalities. Of the 173 survivors, 50 (28.9%) had mild, 102 (59%) moderate, and 21 (12.1%) severe disease. Severe cases showed significant declines in estimated glomerular filtration rate and higher rates of renal replacement therapy and acute rejection versus mild and moderate cases. Mean loss of glomerular filtration rate in 2 years among patients with severe COVID was 9 mL/min/m2. Graft and patient survival rates were also worse in moderate and severe COVID groups.</p><p><strong>Conclusions: </strong>Kidney transplant recipients with mode-rate and severe COVID-19 experienced significant long-term declines in renal function and increased graft loss and mortality. Understanding these effects is critical for optimizing care for this population.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"23 8","pages":"517-522"},"PeriodicalIF":0.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erector Spinae Plane Block for Postoperative Analgesia in Laparoscopic Living-Donor Nephrectomy.","authors":"Bora Dinc, Ilker Onguc Aycan, Ali Avanaz, Nihal Kiraz, Abdullah Kisaoglu, Necmiye Hadimioglu, Zeki Ertug, Ismail Demiryilmaz","doi":"10.6002/ect.2022.0401","DOIUrl":"10.6002/ect.2022.0401","url":null,"abstract":"<p><strong>Objectives: </strong>Postoperative donor care is being improved with newly applied methods. Recently, because of its effectiveness, erector spinae plane blocks have been increasing in popularity. However, its use for laparoscopic living-donor nephrectomy is not fully known. We evaluated the effectiveness of erector spinae plane blocks in laparoscopic living-donor nephrectomy on postoperative pain and total analgesia consumption in the first 24 hours postsurgery.</p><p><strong>Materials and methods: </strong>In this randomized, prospective cohort efficiency study, we included 60 donors scheduled for elective nephrectomy. The control group (n = 30) received analgesic medication according to organ transplant ward protocol for postoperative pain treatment; the erector spinae plane block group (n = 30) underwent an erector spinae plane block application with routine analgesic medication practice. We evaluated the efficacy of postoperative pain treatment and total analgesic consumption at postoperative 1, 6, 12, and 24 hours.</p><p><strong>Results: </strong>Among the 60 donors in the study, there were no differences in the verbal numerical rating scale and the Wong-Baker Faces Pain Rating Scale scores between the groups in the first 24 hours. However, total tramadol consumption in the erector spinae plane block group was less (P = .003) than in the control group. Regression analysis confirmed that block application was associated with tramadol consumption (P = .001).</p><p><strong>Conclusions: </strong>Although erector spinae plane blocks applied under bilateral ultrasonographic guidance did not have any efficacy for pain relief in the first 24 hours postoperation, a decrease was found in analgesic consumption compared with the nonblock group.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"23 8","pages":"523-529"},"PeriodicalIF":0.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare Presentation of Posttransplant Lymphoproliferative Disease in a Pediatric Liver Transplant Recipient: Plasmablastic Lymphoma Complicated With Hemophagocytic Lymphohistiocytosis.","authors":"Burcu Belen Apak, Pamir Işık, Figen Özçay, Oya Balcı Sezer, Pelin Bayık, Lale Olcay, Mehmet Coşkun, Emre Karakaya, Mehmet Haberal","doi":"10.6002/ect.2024.0326","DOIUrl":"https://doi.org/10.6002/ect.2024.0326","url":null,"abstract":"<p><p>A 3-year-old female patient, who had received a liver transplant from her father 1 year previously to treat biliary atresia, was admitted with fever and pancytopenia. History showed Epstein-Barr virus polymerase chain reaction positivity detected in the patient 3 months earlier; the patient received reduced immunosuppression in doses of tacrolimus, and valganciclovir was administered. Physical exa-mination showed lymphadenopathies at the cervical, axillary and inguinal regions with 2 × 2 cm at diameter, splenomegaly of 5 cm, and fever of 39 °C. Considering the clinical setting of immune suppression, the patient was diagnosed with monomorphic posttransplant lymphoproliferative disorder in the form of plasmablastic lymphoma. The pancytopenia of the patient could not be explained with plasmablastic lymphoma; therefore, a concomitant hemophagocytic lymphohistiocytosis was suspected. The patients was changed from tacrolimus to sirolimus followed by 6 days of induction therapy and received a combination regimen of cyclophosphamide, doxorubicin, prednisolone, and vincristine every 21 days for 4 to 6 cycles plus rituximab 375 mg/m2/wk for 4 weeks. For hemophagocytic lymphohistiocytosis, the patient received intravenous immunoglobulin 1 g/kg every week for 4 weeks, followed by monthly therapy during chemotherapy cycles. After 2 courses of chemotherapy and 4 doses of rituximab, lymph nodes and splenomegaly disappeared, blood tests returned to standard levels, and Epstein-Barr virus polymerase chain reaction results were negative. Positron emission tomography computed tomography after 2 cycles showed complete remission of disease. After 5 cycles of chemotherapy, the patient remained well without any complications.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"23 8","pages":"565-568"},"PeriodicalIF":0.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unexpected Diagnosis of Non-Hodgkin Lymphoma After Liver Transplant: A Case Report of Suspected Neuroendocrine Tumor Recurrence Managed with Robotic Distal Pancreatectomy and Splenectomy.","authors":"Urjita Das, Srinivasan Muthukrishnan, Miranda James, Seung Tae Lee, Raphael Pascal Henri Meier, Chandra Shekhar Bhati","doi":"10.6002/ect.2025.0117","DOIUrl":"https://doi.org/10.6002/ect.2025.0117","url":null,"abstract":"<p><p>The development of non-Hodgkin lymphoma following liver transplant is rare. We present an unusual case of a 40-year-old female patient with morbid obesity who had undergone a deceased donor liver transplant for an unresectable neuroendocrine tumor of the liver 12 years ago. She presented with a lesion in the tail of pancreas that was suggestive of a recurrent neuroendocrine tumor. She underwent robotic-assisted distal pancre-atectomy and splenectomy, which demonstrated a final diagnosis of splenic marginal zone lymphoma. Although there is a high likelihood of recurrence of neuroen-docrine tumor after transplant, non-Hodgkin lymphoma and posttransplant lymphoproliferative disorder must be considered in the background of transplant and solid-organ malignancy.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"23 8","pages":"560-564"},"PeriodicalIF":0.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Affecting Timeline of Kidney Transplant Evaluation Process in Saudi Arabia.","authors":"Zainab Habibullah, Muhammed Bukhari","doi":"10.6002/ect.2025.0121","DOIUrl":"10.6002/ect.2025.0121","url":null,"abstract":"<p><strong>Objectives: </strong>Patients who reach the terminal phase of renal disease are candidates for kidney transplant. However, the pretransplant process is substantial and requires time-intensive evaluations. We aimed to investigate the factors that affect the timeline for evaluation of kidney transplants and to identify the challenges and recommendations for improvement of the evaluation process in Saudi Arabia.</p><p><strong>Materials and methods: </strong>For the first part of the study, we collected retrospective data from all patients who underwent kidney transplant from 2017 to 2022 at King Abdullah Medical City, Makkah, Saudi Arabia. For the second part of the study, we used a cross-sectional design to collect health workers' perceptions of the factors, recommendations, and challenges in the kidney transplant evaluation process at King Abdullah Medical City.</p><p><strong>Results: </strong>The average number of specialty clinic visits was 7.43, and the average number of clinic visits was 21.37. The mean wait time for surgery was 185.5 days (SD, 106.91 days). There was a significant positive correlation between the wait time for surgery and the total number of clinics visited (r = 0.286, P = .026).</p><p><strong>Conclusions: </strong>This study provides valuable insightsinto the factors that may affect kidney transplant evaluation in Saudi Arabia, and our results emphasize the importance of adequate resources and effective teamwork.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"23 8","pages":"530-534"},"PeriodicalIF":0.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protection of the Endothelium and Endothelial Glycocalyx by Albumin and Sulodexide in Porcine Model of Kidney Transplant.","authors":"Pavel Navratil, Jiri Chalupnik, David Rehak, Diana Gorskaja, Alena Ticha, David Weishaupt, Dana Cizkova, Eva Cermakova, Ales Bezrouk, David Astapenko","doi":"10.6002/ect.2024.0222","DOIUrl":"https://doi.org/10.6002/ect.2024.0222","url":null,"abstract":"<p><strong>Objectives: </strong>Kidney transplant is a life-saving procedure for patients with end-stage renal disease. Success of kidney transplant is highly dependent on maintaining the integrity of the endothelium and its protective layer, the endothelial glycocalyx. Ischemia-reperfusion injury, a common challenge in kidney transplant, can disrupt the endothelial glycocalyx, leading to various post-transplant complications. We investigated the effects of albumin and sulodexide, 2 therapeutic agents, for protection of the endothelium and endothelial glycocalyx in a porcine model of kidney transplant.</p><p><strong>Materials and methods: </strong>Fourteen female piglets were prepared for kidney transplant simulation and randomly divided into 3 groups: a control group, an albumin-treated group, and a sulodexide-treated group. Various physiological parameters were monitored, and samples for serum and urine were collected at baseline and at multiple time points after reperfusion. Integrity of the endothelial glycocalyx was assessed from serum syndecan-1 levels and urinary glycosaminoglycan concentrations. Histology of the renal cortex allowed evaluation of tissue changes following the intervention.</p><p><strong>Results: </strong>Statistically significant differences were observed in the sulodexide-treated group, where serum syndecan-1 levels were lower versus the control group at 5 minutes after reperfusion (P = .046), indicating a potential reduction in endothelial glycocalyx damage. Similarly, in the albumin-treated group, urinary glycosaminoglycan levels were significantly lower versus the control group at 5 minutes after reperfusion (P = .041), which may suggest a protective effect on the endothelial glycocalyx. However, these findings are preliminary, and no other significant differences were detected between the treatment groups and the control group at later time points. Histology of the renal cortex revealed that the changes were generally minor across all groups.</p><p><strong>Conclusions: </strong>We suggest that albumin and sulodexide may offer beneficial effects in preserving endothelial function during kidney transplant. The potential for these agents to enhance graft survival and improve kidney transplant outcomes warrants further investigation.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"23 8","pages":"509-516"},"PeriodicalIF":0.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Hepatic Arterial Reconstruction prior to On-Site Normothermic Machine Perfusion in Donation after Circulatory Death Liver Transplant.","authors":"Jaffe Emily, Toshihide Tomosugi, Alban Longchamp, Richard Teo, Shoko Kimura, John Montgomery, Lyle Burdine, James Markmann, Heidi Yeh, Tsukasa Nakamura","doi":"10.6002/ect.2025.0140","DOIUrl":"10.6002/ect.2025.0140","url":null,"abstract":"<p><strong>Objectives: </strong>On-site normothermic machine perfusion of the liver may require hepatic arterial reconstruction. The effect of arterial reconstruction on the deve-lopment of primary ischemic cholangiopathy has not been fully elucidated in liver transplants with organs donated after circulatory death. The aim of this study was to evaluate the effect of normothermic machine perfusion with arterial reconstruction at the onset of ischemic cholangiopathy in liver transplants with organs donated after circulatory death.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed 93 patients who had received liver transplants donated after circulatory death for the period from 2015 to 2023 at a single institution. The primary endpoint was the onset of primary ischemic cholangiopathy within 1 year after donation after circulatory death liver transplant, excluding secondary ischemic cholangiopathy due to arterial complications.</p><p><strong>Results: </strong>Normothermic machine perfusion was used for 71 cases, whereas standard cold storage was applied for 22 cases. Arterial reconstruction was performed in 14.1% of cases versus 27.3% of cases without normothermic machine perfusion. The cumulative onset of ischemic cholangiopathy was 7.0% versus 27.2% without normothermic machine perfusion (P = .013). In the group with normothermic machine perfusion, competing risk analyses demonstrated that the cumulative ischemic cholangiopathy onset rate was significantly higher in the group with arterial reconstruction (30.0%) versus without arterial reconstruction (3.3%) (P < .003). Total cold ischemia time and cold ischemia time between liver recovery and normothermic machine perfusion initiation were significantly longer in the group with arterial reconstruction (P < .001), without significant differences in arterial flow on normothermic machine perfusion and other relevant factors.</p><p><strong>Conclusions: </strong>In donation after circulatory death liver transplant recipients with normothermic machine perfusion, arterial reconstruction is a risk factor for developing ischemic cholangiopathy, likely mediated by cold ischemia time prolongation.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"23 8","pages":"535-541"},"PeriodicalIF":0.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver Fibrosis and Quality of Life in Liver Transplant Recipients Over 10 Years: A Cross-Sectional Study Using Transient Elastography.","authors":"Nilay Daniş, Hüseyin Döngelli, Tarkan Ünek, Tufan Egeli, Cihan Ağalar, Mücahit Özbilgin, Mesut Akarsu","doi":"10.6002/ect.2025.0114","DOIUrl":"https://doi.org/10.6002/ect.2025.0114","url":null,"abstract":"<p><strong>Objectives: </strong>Liver transplant has significantly improved the survival of patients with end-stage liver disease, yet long-term transplant recipients often face challenges related to graft function and well-being. We aimed to evaluate the clinical role of vibration-controlled transi-ent elastography for assessment of liver fibrosis and steatosis, with a focus on fibrosis and steatosis, in liver transplant recipients who were over 10 years posttrans-plant. In addition, we aimed to identify factors that influence liver function and quality of life in these patients.</p><p><strong>Materials and methods: </strong>This prospective, crosssectional study included 105 liver transplant recipients. Vibration-controlled transient elastography measurements (controlled attenuation parameter and liver stiffness measurement) were used to assess liver steatosis and fibrosis, and the Short Form 36 quality of life questionnaire was use to evaluate overall health of patients. Demographic data, medical history, and laboratory results were also collected. Generalized linear models identified significant factors that may affect liver function and quality of life.</p><p><strong>Results: </strong>No significant differences were observed between liver transplant recipients with living donors versus recipients with deceased donors with regard to fibrosis, quality of life, or other factors. The study found that diabetes mellitus (controlled attenuation parameter: P = 0.278; 95% CI, 0.193-0.363; P < .001) and history of biopsy-proven rejection (liver stiffness measurement: β = 0.814; 95% CI, 0.653-0.975; P < .001) were key factors associated with greater severity of liver steatosis and fibrosis. Significant fibrosis was associated with lower physical function scores (β = -0.207; P = .040).</p><p><strong>Conclusions: </strong>Vibration-controlled transient elastography is a valuable tool for assessment of liver fibrosis and steatosis in long-term liver transplant recipients and thereby facilitates optimization of posttransplant care and improved outcomes.</p>","PeriodicalId":50467,"journal":{"name":"Experimental and Clinical Transplantation","volume":"23 8","pages":"546-554"},"PeriodicalIF":0.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}